<DOC>
	<DOCNO>NCT01167088</DOCNO>
	<brief_summary>The purpose study investigate whether new medicine , call mitoquinone , reduce raise liver enzyme due NAFLD see safe .</brief_summary>
	<brief_title>A Study Compare MitoQ Placebo Treat Non-alcoholic Fatty Liver Disease ( NAFLD )</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Provide write informed consent 2 . NAFLD determine raise ALT ( &gt; 1.5 x ULN correspond &gt; 29U/L female &gt; 45U/L male ] screening period least two occasion previous 6 month ) ultrasound evidence steatosis ( previous 12 month ) . 3 . Be age 18 70 year day consent 4 . Expect require make change current concomitant medication ( prescribed overthecounter ) duration participation study 5 . Female patient reproductive potential must negative serum pregnancy test within 14 day prior start trial must agree use medically acceptable method contraception throughout treatment period 1 month discontinuation treatment . Acceptable method contraception include IUD , oral contraceptive , subdermal implant double barrier ( condom contraceptive sponge contraceptive pessary ) 1 . Alcohol consumption &gt; 14 units/week female 21 units/week male 2 . Hepatocellular carcinoma ( HCC ) suspicion HCC 3 . Presence human immunodeficiency virus ( HIV ) , Hepatitis B ( HBV ) Hepatitis C ( HCV ) 4 . Renal impairment ( creatinine &gt; 1.5 x ULN ) hepatorenal syndrome 5 . Chronic pancreatitis 6 . Hospitalization liver disease within 60 day baseline visit 7 . Previously diagnose diabetes / treatment insulin sensitize agent 8 . Severe morbid obesity ( BMI &gt; 40kg/m2 ) 9 . ALT AST &gt; 10 time ULN 10 . Liver transplant recipient 11 . Corticosteroids past 30 day 12 . Any participant receive investigational drug device within 30 day dose , schedule receive another investigational drug device course trial 13 . A history malignancy treat basal cell squamous cell carcinoma skin ; history malignancy treat recurrence within last 2 year exclude 14 . Females pregnant breastfeed 15 . Use Coenzyme Q10 , either prescribe purchased overthecounter , prohibit study , except dos 25mg/day stable 30 day prior baseline . Higher dos require 7 day washout prior baseline . 16 . Use Vitamin E , either prescribe purchased overthecounter , prohibit study , except dos 200IU/day stable 30 day prior baseline . Higher dos require 90 day washout prior baseline . 17 . Any change prescription medication 30 day prior baseline 18 . A history hypersensitivity reaction component study drug structurally similar compound include Coenzyme Q10 idebenone 19 . Unable swallow tablet whole 20 . Patients histological clinical evidence establish cirrhosis 21 . Suffering disease condition , opinion investigator , mean would patient 's best interest participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Double-blind</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Non-alcoholic fatty liver disease</keyword>
	<keyword>NAFLD</keyword>
</DOC>